Pediatric Leukemia and Lymphoma Steering Committee
The Pediatric Leukemia and Lymphoma Steering Committee (PLLSC) was established in 2011. PLLSC members include representatives from the Children's Oncology Group, pediatric and medical oncologists and other specialists, translational scientists, biostatisticians, patient advocates, and NCI staff. At monthly meetings, the PLLSC addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in pediatric hematologic cancers. View the PLLSC member roster.
- PLLSC Strategic Priorities address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment. They were formulated by the PLLSC in conjunction with the Children’s Oncology Group (COG) with the goal that the majority of submitted concepts would align with the established priorities. Strategic priorities are currently available for acute lymphoblastic leukemia and myeloid leukemia. Strategic priorities for other diseases are forthcoming.
Clinical Trial Planning Meetings (CTPMs)
CTPMs are held periodically and focus on specific clinical trial related topics. The following are important PLLSC CTPMs:
- Minimal Residual Disease in Adult Leukemia
Minimal residual disease (MRD) is the leukemic cells remaining in the blood after initial treatment for leukemia measured by either flow cytometry or DNA-based methods. It is an important prognostic tool but requires standardization for use in clinical trials. Two workshops were held in 2012 to address standardization. Because of the importance of MRD assessment in pediatric leukemia, researchers from COG as well as PLLSC members took part in these workshops.
For more information, contact Wolf Lindwasser, Ph.D. at email@example.com.